Get the Stockscreener App
6.88
5.36%
0.35
Pre-market:
7.21
0.33
+4.80%
Recursion Pharmaceuticals Inc stock is traded at $6.88, with a volume of 12.70M.
It is up +5.36% in the last 24 hours and up +14.10% over the past month.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
See More
Previous Close:
$6.53
Open:
$6.74
24h Volume:
12.70M
Relative Volume:
1.09
Market Cap:
$2.69B
Revenue:
$64.60M
Net Income/Loss:
$-377.75M
P/E Ratio:
-4.4387
EPS:
-1.55
Net Cash Flow:
$-335.64M
1W Performance:
+8.86%
1M Performance:
+14.10%
6M Performance:
-9.59%
1Y Performance:
-28.56%
1-Day Range:
$6.6641
$7.17
1-Week Range:
$6.33
$7.17
52-Week Range:
$5.60
$15.74
Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile
Name
Recursion Pharmaceuticals Inc
Sector
Industry
Phone
(385) 269-0203
Address
41S RIO GRANDE STREET, SALT LAKE CITY
Compare RXRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
6.88 | 2.69B | 64.60M | -377.75M | -335.64M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-22-23 | Initiated | Morgan Stanley | Equal-Weight |
| Mar-16-23 | Initiated | Needham | Buy |
| Sep-16-22 | Initiated | KeyBanc Capital Markets | Overweight |
| Apr-18-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-04-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-21-21 | Initiated | Berenberg | Buy |
| May-11-21 | Initiated | BofA Securities | Buy |
| May-11-21 | Initiated | Goldman | Neutral |
| May-11-21 | Initiated | JP Morgan | Neutral |
| May-11-21 | Initiated | KeyBanc Capital Markets | Overweight |
| May-11-21 | Initiated | SVB Leerink | Outperform |
View All
Recursion Pharmaceuticals Inc Stock (RXRX) Latest News
(RXRX) Investment Analysis - Stock Traders Daily
2 Growth Stocks That Could Rocket Higher in the First Quarter of 2025 - MSN
Avanza Fonder AB Takes Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - MarketBeat
Recursion posts mid-stage data for lead asset - MSN
Recursion Pharmaceuticals, Inc. (RXRX): Revolutionizing Drug Discovery with AI and Strategic Collaborations for Strong Growth - Insider Monkey
Blackrock’s 30 Most Important AI Stocks - Insider Monkey
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought - AOL
Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 4.5%Still a Buy? - MarketBeat
Is Recursion Pharmaceuticals Stock a Buy? - MSN
Recursion Pharmaceuticals (RXRX) Rises Yet Lags Behind Market: Some Facts Worth Knowing - MSN
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 3.6%Should You Sell? - MarketBeat
Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 0.5% HigherStill a Buy? - MarketBeat
Recursion Pharmaceuticals, Inc. (RXRX) Stock Price, News, Quote & History - Yahoo Finance
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 4.8%What's Next? - MarketBeat
Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 4.4% HigherTime to Buy? - MarketBeat
JPM25: Recursion $RXRXby AlbertRhymes with Haystack - substack.com
Why Recursion Pharmaceuticals Shares Are Dropping - TipRanks
Recursion Pharmaceuticals CEO sells shares worth $287,200 By Investing.com - Investing.com Nigeria
Recursion Pharmaceuticals CEO sells shares worth $287,200 - Investing.com India
Recursion Pharmaceuticals Showcases Progress at JP Morgan Conference - TipRanks
Recursion Pharmaceuticals: Betting Big On AI (NASDAQ:RXRX) - Seeking Alpha
Does Recursion Pharmaceuticals (RXRX) Have the Potential to Rally 27.96% as Wall Street Analysts Expect? - MSN
Long Term Trading Analysis for (RXRX) - Stock Traders Daily
Cathie Wood's Ark Invest Loads Up On Intellia Therapeutics Which Laid Off Over A Quarter Of Its Workforce - Benzinga
Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 4.3%Time to Sell? - MarketBeat
Recursion: Investors Will Need To Be Patient (NASDAQ:RXRX) - Seeking Alpha
Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 3.1% Following Analyst Downgrade - MarketBeat
Recursion Pharmaceuticals (NASDAQ:RXRX) Price Target Cut to $10.00 by Analysts at KeyCorp - MarketBeat
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 4.4%Time to Sell? - MarketBeat
Recursion Pharmaceuticals price target lowered to $10 from $12 at BofA - Yahoo Finance
Recursion advances two cancer drug trials By Investing.com - Investing.com Australia
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 2.4%Should You Sell? - MarketBeat
Stock Traders Buy High Volume of Recursion Pharmaceuticals Call Options (NASDAQ:RXRX) - MarketBeat
Recursion advances two cancer drug trials - Investing.com
RXRXRecursion Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 6.9%Time to Buy? - MarketBeat
Recursion to Present at 43rd Annual JP Morgan Healthcare Conference - Marketscreener.com
Recursion CEO to Present Pipeline and Platform Updates at JP Morgan Healthcare Conference - StockTitan
Iambic Therapeutics Taps Former Recursion CFO to Lead Financial Strategy and Development - StockTitan
Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 5.3% HigherShould You Buy? - MarketBeat
Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 8.1%Time to Buy? - MarketBeat
Recursion Pharmaceuticals Inc Stock (RXRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):